Phase 2 N=8 Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP
Purpura, Thrombocytopenic, Idiopathic
Primary: Free Hemoglobin — 13.057; 12.371 g/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=350 A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma
Asthma
Primary: Final Dose-response Model for Trough Forced Expiratory Volume in One Second (FEV1) — 0.0363; -0.97; 0.00371; 0.149 unitless
Phase 2 N=24 PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation
Multiple Myeloma
Primary: Area Under the Curve (0-t) — 376577; 341183 min*ng/mL
Phase 2 N=9 Topical Bimatoprost Effect on Androgen Dependent Hair Follicles
Male Pattern Hair Loss · Androgenetic Alopecia
Primary: Percent Change in Target Area Total Hair Count — -2.6; 27.4; 4.9; -5.8 percentage change in total hair count
Phase 2 N=65 Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction
Adenocarcinoma of the Gastroesophageal Junction · Esophageal Cancer
Primary: Number of Participants With Pathologic Complete Response Following Surgery — 18 participants
Phase 2 N=141 A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer
Breast Cancer
Primary: Progression-Free Survival (PFS) — 4.4; 4.1 months
Phase 2 N=25 Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1
HIV-1 Infection · HIV Infections
Primary: Percentage of Participants With Plasma HIV-1 RNA >50 — 12.5 percentage of participants
Phase 2 N=135 Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus
Diabetes Mellitus, Type 1
Primary: Change From Baseline in Glycosylated Hemoglobin A1C (HbA1c) at the End of Each Treatment Period — -0.14; -0.19 percentage of hemoglobin A1C — p=0.2878
Phase 2 N=241 Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion
Persistent Atrial Fibrillation
Primary: Time From Randomization to First Documented AF Recurrence. — 51.0; NA; 117.0; 58.0 Days
Phase 2 N=23 Beta Glucosylceramide for Treatment of NASH
Compliance Behavior
Primary: Number of Participants With a Decrease of 2 Points in the Non-Alcoholic Fatty Liver Disease Activity Score (NAS) Analysis is Per Protocol — 10; 13 participants
Phase 2 N=37 BIBF 1120 for Recurrent High-Grade Gliomas
Glioblastoma · Gliosarcoma · Anaplastic Astrocytoma
Primary: 6-Month Progression Free Survival — 0 percentage of participants
Phase 2 N=23 Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)
Diabetes Mellitus, Type 2
Primary: Postprandial Glucose (PPG) Excursion Following a Liquid Meal — 162.71; 144.67; 169.38; 166.05 Milligrams per deciliter (mg/dL) — p=0.0034
Phase 2 N=171 Green Tea and Tai Chi for Bone Health
Osteoporosis
Primary: Change From Baseline (100%) in Ratio of Bone Formation Marker to Bone Resorption Marker — 106.1; 103.6; 112.3; 113.0 percentage change from baseline
Phase 2 N=22 Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Primary: Complete Response Rate — 36 percentage of patients
Phase 2 N=50 A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.
Colorectal Cancer
Primary: Percentage of Participants With Objective Response (OR) — 42.86 percentage of participants — p=0.0047